Opportunity Information: Apply for PA 16 251
Apply for PA 16 251
- The HHS-NIH11 in the education, health sector is offering a public funding opportunity titled "Gene Fusions in Pediatric Sarcomas (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.396,.
- This funding opportunity was created on May 10, 2016 and posted on May 10, 2016.
- Applicants must submit their applications by May 07, 2019. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Gene Fusions in Pediatric Sarcomas (R01) opportunity (Funding Opportunity Number PA-16-251) is a discretionary NIH research grant announcement under HHS (Agency listed as HHS-NIH11). It focuses on pediatric sarcomas driven by chromosomal translocations that create oncogenic fusion genes. The central purpose is to support R01-level research that explains, in molecular and mechanistic terms, how these fusion genes and the proteins they encode initiate sarcoma formation, push tumors to progress, and enable metastasis. The announcement is built around the idea that fusion-driven sarcomas often rely on specific, abnormal pathways triggered by these translocations, and that defining those pathways can clarify how the cancers start and evolve, while also pointing to therapeutic vulnerabilities that could be exploited for new treatments.
Scientifically, the FOA emphasizes understanding the downstream consequences of fusion events: which molecular pathways become activated or rewired, how those pathways influence oncogenesis and tumor behavior, and how fusion products function in the context of developing tissues typical of pediatric disease. The work encouraged by the announcement is strongly mechanism-oriented, aiming beyond cataloging fusions toward explaining how they operate at the gene regulation, signaling, epigenetic, and cellular levels, and how those effects translate into clinically important behaviors like invasion and spread. By drawing links between translocation-driven biology and tumor progression, the program aims to advance both fundamental cancer pathogenesis knowledge and translational leads for targeted or pathway-informed therapeutics.
From an administrative standpoint, this is an R01 grant mechanism, meaning it is intended for substantial, hypothesis-driven projects with a clear research plan, milestones, and a scope appropriate for a standard NIH research project grant. The activity category is listed under Education and Health, and the CFDA numbers associated with the opportunity are 93.396 (and another listing of 93.396 in the provided data). The FOA was posted and created on May 10, 2016, and the closing date shown in the data is May 7, 2019 (both original and current closing dates match). The dataset does not specify an award ceiling or expected number of awards, so applicants would typically look to NIH institute guidance and the FOA text for budget expectations, paylines, and programmatic priorities at the time of submission.
Eligibility is broad and includes most common applicant types that participate in NIH funding. Eligible applicants listed include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments as well as other tribal organizations; public housing authorities/Indian housing authorities; nonprofit organizations with and without 501(c)(3) status (excluding institutions of higher education in those nonprofit categories); for-profit organizations other than small businesses; and small businesses. The FOA also notes an "Others" category with a reference to additional eligibility details, which usually means NIH may allow other organizations if they meet specific criteria described in the full announcement.
In practical terms, the opportunity is aimed at research teams that can connect pediatric sarcoma genetics to actionable biology, especially where fusion genes are the primary oncogenic drivers. The intended impact is to move the field from identifying translocations to understanding their precise functional roles in tumor initiation, maintenance, progression, and metastatic behavior, with the longer-term goal of enabling new therapeutic strategies grounded in the molecular pathways controlled by fusion oncogenes.
Frequently Asked Questions (FAQs): Gene Fusions in Pediatric Sarcomas (R01) - PA-16-251
What is the Gene Fusions in Pediatric Sarcomas (R01) funding opportunity?
This is an NIH discretionary research grant opportunity (R01 mechanism) focused on pediatric sarcomas driven by chromosomal translocations that create oncogenic fusion genes. The Funding Opportunity Number (FON) is PA-16-251.
Which agency is offering this grant?
The opportunity is offered under the U.S. Department of Health and Human Services (HHS) through the National Institutes of Health (NIH). The agency is listed as HHS-NIH11 in the provided data.
What is the main scientific purpose of this FOA?
The central purpose is to support R01-level research that explains, in molecular and mechanistic terms, how fusion genes (and the fusion proteins they encode) initiate sarcoma formation, drive tumor progression, and enable metastasis.
What types of cancers does the announcement focus on?
The FOA focuses on pediatric sarcomas where chromosomal translocations generate oncogenic fusion genes and where those fusion events are primary drivers of the disease.
What does the FOA mean by "fusion-driven" pediatric sarcomas?
It refers to sarcomas in which chromosomal translocations create abnormal fusion genes that act as key oncogenic drivers. The FOA highlights that these tumors may rely on specific abnormal pathways triggered by the translocations.
What kind of research approach is emphasized?
The announcement emphasizes mechanism-oriented research. It is aimed at moving beyond simply identifying or cataloging gene fusions and toward explaining how they function at molecular and mechanistic levels.
What specific biological questions does this opportunity encourage researchers to address?
It encourages studies on the downstream consequences of fusion events, including which molecular pathways become activated or rewired, how those pathways influence oncogenesis and tumor behavior, and how fusion products function in the context of developing tissues typical of pediatric disease.
Which mechanistic areas are highlighted as relevant to this FOA?
The FOA highlights mechanistic understanding across gene regulation, signaling, epigenetic changes, and cellular-level effects, and how these translate into clinically important behaviors such as invasion and metastatic spread.
Is this opportunity intended to support translational research?
The stated intent includes identifying therapeutic vulnerabilities by defining fusion-driven pathways, which can point to translational leads for targeted or pathway-informed therapeutics. The emphasis remains strongly on explaining mechanisms and linking them to tumor behavior and progression.
What is an R01 mechanism in the context of this announcement?
An R01 is a standard NIH Research Project Grant mechanism intended for substantial, hypothesis-driven projects with a clear research plan and a scope appropriate for a standard NIH research project grant.
What level of project scope is implied by the R01 mechanism here?
The FOA is intended for substantial projects that can support a clear, hypothesis-driven research plan with milestones and enough depth to explain fusion gene function in tumor initiation, progression, and metastasis.
What outcomes or impacts is this FOA trying to achieve?
The intended impact is to advance fundamental knowledge of cancer pathogenesis by clarifying how translocation-driven biology supports tumor initiation and evolution, while also generating insights that may enable new therapeutic strategies grounded in fusion-controlled pathways.
What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number is PA-16-251.
What is the title of the opportunity?
The title provided is Gene Fusions in Pediatric Sarcomas (R01).
What is the activity category for this opportunity?
The activity category is listed under Education and Health.
What CFDA number(s) are associated with this opportunity?
The CFDA number listed is 93.396 (it appears twice in the provided data).
When was this FOA posted/created?
The FOA was posted and created on May 10, 2016.
What is the closing date for this opportunity?
The closing date shown in the provided data is May 7, 2019, and the original and current closing dates match.
Does the dataset specify an award ceiling or the expected number of awards?
No. The dataset does not specify an award ceiling or an expected number of awards.
Where should applicants look for budget expectations or award volume details?
Because the dataset does not provide an award ceiling or expected number of awards, applicants would typically look to NIH institute guidance and the full FOA text for budget expectations, paylines, and programmatic priorities at the time of submission.
Who is eligible to apply for this grant opportunity?
Eligibility is broad and includes many common NIH applicant types, including various government entities, higher education institutions, tribal governments and organizations, nonprofit organizations (with and without 501(c)(3) status, excluding institutions of higher education in those nonprofit categories), for-profit organizations (other than small businesses), and small businesses.
Are state governments eligible to apply?
Yes. State governments are listed as eligible applicants.
Are county governments eligible to apply?
Yes. County governments are listed as eligible applicants.
Are city or township governments eligible to apply?
Yes. City or township governments are listed as eligible applicants.
Are special district governments eligible to apply?
Yes. Special district governments are listed as eligible applicants.
Are independent school districts eligible to apply?
Yes. Independent school districts are listed as eligible applicants.
Are public or state-controlled institutions of higher education eligible?
Yes. Public and state-controlled institutions of higher education are listed as eligible applicants.
Are private institutions of higher education eligible?
Yes. Private institutions of higher education are listed as eligible applicants.
Are federally recognized Native American tribal governments eligible?
Yes. Federally recognized Native American tribal governments are listed as eligible applicants.
Are other Native American tribal organizations eligible?
Yes. Other Native American tribal organizations are listed as eligible applicants.
Are public housing authorities eligible to apply?
Yes. Public housing authorities and Indian housing authorities are listed as eligible applicants.
Are nonprofit organizations eligible to apply?
Yes. Nonprofit organizations with 501(c)(3) status (excluding institutions of higher education under that nonprofit category) and nonprofit organizations without 501(c)(3) status (also excluding institutions of higher education under that nonprofit category) are listed as eligible applicants.
Are for-profit organizations eligible to apply?
Yes. For-profit organizations other than small businesses are listed as eligible applicants, and small businesses are also listed as eligible applicants.
What does the "Others" eligibility category mean in this announcement?
The FOA notes an "Others" category with a reference to additional eligibility details. This generally indicates there may be additional eligible organization types if they meet specific criteria described in the full announcement.
What kind of applicant teams is this FOA practically aimed at?
It is aimed at research teams that can connect pediatric sarcoma genetics to actionable biology, particularly in cancers where fusion genes are primary oncogenic drivers.
Does the FOA prioritize identifying new gene fusions?
The emphasis described is not on cataloging fusions alone. The FOA is framed around defining the downstream consequences and mechanisms of known or discovered fusion events, and linking those mechanisms to tumor initiation, progression, and metastasis.
How does this FOA connect fusion biology to therapy development?
By defining abnormal pathways triggered by fusion genes and how those pathways shape tumor behavior, the program aims to reveal therapeutic vulnerabilities that could be exploited for new treatments, including targeted or pathway-informed approaches.
Browse more opportunities from the same category: Education, Health
Next opportunity: BLM-Arizona, Tread Lightly! Sonoran Landscape Project ASO
Previous opportunity: Prescription Drug Abuse (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 16 251
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 16 251) also looked into and applied for these:
| Funding Opportunity |
|---|
| Innovative Approaches to Studying Cancer Communication in the New Media Environment (R01) Apply for PAR 16 249 Funding Number: PAR 16 249 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Gene Fusions in Pediatric Sarcomas (R21) Apply for PA 16 252 Funding Number: PA 16 252 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Innovative Approaches to Studying Cancer Communication in the New Media Environment (R21) Apply for PAR 16 248 Funding Number: PAR 16 248 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Accelerating the Pace of Drug Abuse Research Using Existing Data (R01) Apply for PAR 16 234 Funding Number: PAR 16 234 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $500,000 |
| Building Evidence: Effective Palliative/End of Life Care Interventions (R01) Apply for PAR 16 250 Funding Number: PAR 16 250 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Predicting Behavioral Responses to Population-Level Cancer Control Strategies (R21) Apply for PAR 16 257 Funding Number: PAR 16 257 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Cancer-related Behavioral Research through Integrating Existing Data (R21) Apply for PAR 16 255 Funding Number: PAR 16 255 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Cancer-related Behavioral Research through Integrating Existing Data (R01) Apply for PAR 16 256 Funding Number: PAR 16 256 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Methodology and Measurement in the Behavioral and Social Sciences (R01) Apply for PAR 16 260 Funding Number: PAR 16 260 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Mechanisms of Cancer and Treatment-related Symptoms and Toxicities (R21) Apply for PA 16 258 Funding Number: PA 16 258 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Methodology and Measurement in the Behavioral and Social Sciences (R21) Apply for PAR 16 261 Funding Number: PAR 16 261 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01) Apply for PAR 16 266 Funding Number: PAR 16 266 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Serious Adverse Drug Reaction Research (R21) Apply for PAR 16 274 Funding Number: PAR 16 274 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Serious Adverse Drug Reaction Research (R01) Apply for PAR 16 275 Funding Number: PAR 16 275 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Program to Assess the Rigor and Reproducibility of Exosome-Derived Analytes for Cancer Detection (R01) Apply for PAR 16 276 Funding Number: PAR 16 276 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Fogarty HIV Research Training Program for Low-and Middle-Income Country Institutions (D43) Apply for PAR 16 279 Funding Number: PAR 16 279 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $280,000 |
| Infrastructure Development Training Programs for Critical HIV Research at Low-and Middle-Income Country Institutions (G11) Apply for PAR 16 280 Funding Number: PAR 16 280 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $92,000 |
| Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21) Apply for PAR 16 278 Funding Number: PAR 16 278 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Prescription Drug Abuse (R21) Apply for PA 16 232 Funding Number: PA 16 232 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Planning Grant for Fogarty HIV Research Training Program for Low-and Middle-Income Country Institutions (D71) Apply for PAR 16 281 Funding Number: PAR 16 281 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $28,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 16 251", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.